where does the anti d injection come from
Rho(D) immune globulin Rho(D) immune globulin is a derivative of human plasma. The most common way anti-D products are manufactured is by a form of the Cohn cold ethanol fractionation method developed in the 1950s. Variations of the Cohn method developed in the 1950s may not completely clear aggregates of immunoglobulins, which can cause problems for patients if administered intravenously, and is a primary reason why most anti-Ds are for intramuscular use only. A non-Cohn manufacturing variation is ChromaPlus process approved by the U.S. Food and Drug Administration (FDA) that is used to make Rhophylac.[22] Rho(D) immune globulin may trigger an allergic reaction. Steps are taken in the plasma-donor screening process and the manufacturing process to eliminate bacterial and viral contamination, although a small, residual risk may remain for contamination with small viruses. There is also a theoretical possibility of transmission of the prion responsible for Creutzfeldt–Jakob disease, or of other, unknown infectious agents.[23]
Magic bullet (medicine) In 1906 Ehrlich developed a new derivative of arsenic compound, which he code-named Compound 606 (the number representing the series of all his tested compounds). The compound was effective against malaria infection in experimental animals.[1] In 1905, Fritz Schaudinn and Erich Hoffmann identified a spirochaete bacterium (Treponema pallidum) as the causative organism of syphilis. With this new knowledge, Ehrlich tested Compound 606 (chemically arsphenamine) on a syphilis-infected rabbit. He did not recognise its effectiveness. Sahachiro Hata went over Ehrlich's work and found on 31 August 1909 he found that the rabbit, which had been injected with Salvarsan 606 was cured using only a single dose, the rabbit showed no adverse effect. (The normal treatment procedure of syphilis at the time involved two to four years routine injection with mercury.) Ehrlich, after receiving this information, performed experiments on human patients with the same success. After convincing clinical trials, the compound number 606 was given a trade name "Salvarsan", a portmanteau for "saving arsenic".[2] Salvarsan was commercially introduced in 1910, and in 1913, a less toxic form "Neosalvarsan" (Compound 914) was released in the market. These drugs became the principal treatments of syphilis until the arrival of penicillin and other novel antibiotics towards the middle of the 20th century.[1] Ehrlich's research on the magic bullet was the foundation of pharmaceutical research.[7]